ZURA
Zura Bio Ltd
NASDAQ · Healthcare · Biotechnology · US
$3.81
−1.80%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.98
From 52W high−45.88%
Volume4.54M
Market cap$365.11M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$3.98
From 52W high
−45.88%
Volume
4.54M
Market cap
$365.11M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.9x
P/E (TTM)
—
RSI (14)
35.9
MomentumView details →
1D Return
−1.80%
YTD Return
−26.15%
SummaryUpdated Jun 1, 2026
Zura Bio Limited (NASDAQ:ZURA) is a clinical-stage biotechnology company founded and based in San Diego, California. The company went public in March 2023 and focuses on developing novel therapeutic medicines to treat immune and inflammatory disorders. As a pre-revenue biotechnology firm, Zura Bio is currently advancing multiple drug candidates through clinical trials, with its lead programs targeting specific biological pathways involved in autoimmune and inflammatory diseases.
Similar companies
Latest newsMore news →
Zura Bio Limited granted inducement stock options to purchase up to 587,000 Class A Ordinary Shares to thirteen newly hired employees on August 20, 2026, as inducements material to their employment.59d agoZura Bio Limited announced its financial results for the second quarter ended June 30, 2026, and provided corporate updates.69d ago